Proposal 1 (a):
|
Mr. Ruben Krupik be, and hereby is, re-elected to serve as a director of the Company, effective from the date hereof and until the next annual general meeting of shareholders or until his earlier resignation or removal.
|
|||
For
13,926,406
|
Against
11,009
|
Abstain
8,050
|
Broker Non-Votes
0
|
|
Proposal 1 (b):
|
Mr. Ofer Gonen be, and hereby is, re-elected to serve as a director of the Company, effective from the date hereof and until the next annual general meeting of shareholders or until his earlier resignation or removal.
|
|||
For
13,925,156
|
Against
12,259
|
Abstain
8,050
|
Broker Non-Votes
0
|
|
Proposal 1 (c):
|
Mr. Meron Mann be, and hereby is, re-elected to serve as a director of the Company, effective from the date hereof and until the next annual general meeting of shareholders or until his earlier resignation or removal.
|
|||
For
13,609,356
|
Against
327,309
|
Abstain
8,800
|
Broker Non-Votes
0
|
|
Proposal 1 (d):
|
Dr. Marian Gorecki be, and hereby is, re-elected to serve as a director of the Company, effective from the date hereof and until the next annual general meeting of shareholders or until his earlier resignation or removal.
|
|||
For
13,862,294
|
Against
75,121
|
Abstain
8,050
|
Broker Non-Votes
0
|
|
Proposal 2:
|
Kost Forer Gabbay and Kasierer, a member firm of Ernst & Young, be and hereby is reappointed as the Company’s independent registered public accounting firm for the year ending December 31, 2015, and until the next annual general meeting of shareholders of the Company, and (ii) the Company’s board of directors (with power of delegation to the audit committee) be, and hereby is, authorized, to fix the remuneration of such independent registered public accounting firm in accordance with the volume and nature of its services
|
|||
For
13,936,850
|
Against
5,435
|
Abstain
3,180
|
Broker Non-Votes
0
|
|
Proposal 3:
|
The amended employment terms of Prof. Lior Rosenberg, the Company’s Chief Medical Technology Officer, as described in the Proxy Statement, are hereby approved.
|
|||
For
13,903,785
|
Against
13,859
|
Abstain
27,821
|
Broker Non-Votes
0
|
|
Number of non-controlling and non-interested shareholders voted For
2,262,958
|
Number of non-controlling and non-interested shareholders voted Against
13,859
|
Number of non-controlling and non-interested shareholders voted Abstain
27,821
|
-
|
MEDIWOUND LTD.
|
|||
Date: September 10, 2015
|
By: |
/s/ Sharon Malka
|
|
Name: |
Sharon Malka
|
||
Title: |
Chief Financial & Operation Officer
|